Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atherosclerosis Clear all
Completed No phase listed Observational

A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia

NCT02974179
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Subjects from Study AG-CLI-0206 who received AMG0001
Biological
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jul 21, 2026, 7:10 AM EDT
Completed No phase listed Observational

Registry of Emergent Large VeSsel OCclUsion DuE to IntraCranial AtherosclerosiS

NCT05403593
View directory record Official record
Conditions
Intracranial Stenosis, Large Vessel Occlusion, Mechanical Thrombectomy
Interventions
No Intervention
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
New Haven, Connecticut • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jul 21, 2026, 7:10 AM EDT
Completed No phase listed Observational

Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD Study)

NCT04496544
View directory record Official record
Conditions
Peripheral Arterial Disease, Paclitaxel Adverse Reaction, Safety Issues
Interventions
Retrospective data collection
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
66 Years and older
Enrollment
168,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD?

NCT00032357
View directory record Official record
Conditions
Atherosclerosis, Intermittent Claudication, Peripheral Vascular Diseases
Interventions
Ferritin reduction to 25 ng/ml by phlebotomy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
1,277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • No. Little Rock, Arkansas • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

NCT01873339
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Midazolam
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 21, 2026, 7:10 AM EDT
Recruiting Not applicable Interventional

Serrantor OCT Study

NCT06434194
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Serranator PTA Serration Catheter, PTA (Standard of Care)
Device · Drug
Lead sponsor
Cagent Vascular LLC
Industry
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 3 Interventional

The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC

NCT00071266
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease
Interventions
Niacin Extended Release and Lovastatin Tablets
Drug
Lead sponsor
Kos Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2006 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 2 Interventional

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

NCT00005928
View directory record Official record
Conditions
Atherosclerosis, Coronary Disease, Vasculitis
Interventions
Ramipril
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 7:10 AM EDT
Recruiting Phase 3 Interventional

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Pelacarsen, Placebo, Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Not applicable Interventional Results available

ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent

NCT02574481
View directory record Official record
Conditions
Atherosclerosis of Native Arteries of the Extremities
Interventions
ELUVIA (Stent Implantation), Zilver PTX (Stent Implantation)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
42
States / cities
Yuma, Arizona • Sacramento, California • Gainesville, Florida + 38 more
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Jul 21, 2026, 7:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atherosclerosis in Rheumatoid Arthritis

NCT00990730
View directory record Official record
Conditions
Rheumatoid Arthritis, Endothelial Dysfunction
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Jul 21, 2026, 7:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

NCT02651675
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
AAV directed hLDLR gene therapy
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Jul 21, 2026, 7:10 AM EDT
Withdrawn Phase 2 Interventional

Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

NCT02460081
View directory record Official record
Conditions
Diabetic Foot, Peripheral Arterial Disease
Interventions
PDA-002, Placebo
Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison Of Two Tablet Formulations Of SB-568859

NCT00470145
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB-568859
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Jul 21, 2026, 7:10 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

NCT03773172
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
MEDI6012, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alirocumab and Reverse Cholesterol Transport

NCT03014830
View directory record Official record
Conditions
Atherosclerosis, Coronary Heart Disease
Interventions
Alirocumab, Placebos
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jul 21, 2026, 7:10 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 100 Years
Enrollment
17,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
272
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 215 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

NCT01212900
View directory record Official record
Conditions
Atherosclerosis, Hypercholesterolemia
Interventions
Statins, HMG CoA
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years to 99 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Jul 21, 2026, 7:10 AM EDT
Terminated No phase listed Observational Results available

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

NCT03247972
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Evolocumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Not applicable Interventional Results available

The PQ Bypass Pivotal IDE Intra-arterial Stent Graft Study

NCT04130737
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
TORUS Stent Graft System
Device
Lead sponsor
Endologix
Industry
Eligibility
18 Years to 90 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
32
States / cities
Mesa, Arizona • Phoenix, Arizona • Yuma, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Withdrawn Phase 4 Interventional

The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation

NCT02626169
View directory record Official record
Conditions
Atherosclerosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics of Antiplatelet Response

NCT02234427
View directory record Official record
Conditions
Atherosclerosis
Interventions
Aspirin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Not applicable Interventional

Community Walking Exercise for Patients With Peripheral Artery Disease

NCT02075502
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Exercise therapy, lower extremity ET, peripheral open intervention
Behavioral · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis

NCT02417688
View directory record Official record
Conditions
Carotid Atherosclerosis
Interventions
Cu[64]-25%-CANF-Comb PET-MR
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jul 21, 2026, 7:10 AM EDT